72 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Outeiro TF, Alcalay RN, Antonini A, Attems J, Bonifati V, Cardoso F, Chesselet MF, Hardy J, Madeo G, McKeith I, Mollenhauer B, Moore DJ, Rascol O, Schlossmacher MG, Soreq H, et al. Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease". Movement Disorders : Official Journal of the Movement Disorder Society. PMID 37156737 DOI: 10.1002/mds.29419  0.306
2023 El Kodsi DN, Tokarew JM, Sengupta R, Lengacher NA, Chatterji A, Nguyen AP, Boston H, Jiang Q, Palmberg C, Pileggi C, Holterman CE, Shutinoski B, Li J, Fehr TK, LaVoie MJ, ... ... Schlossmacher MG, et al. Parkin coregulates glutathione metabolism in adult mammalian brain. Acta Neuropathologica Communications. 11: 19. PMID 36691076 DOI: 10.1186/s40478-022-01488-4  0.737
2023 Jensen PH, Schlossmacher MG, Stefanis L. Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α-Synuclein. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 36645106 DOI: 10.1002/mds.29318  0.302
2021 Oliveira LMA, Gasser T, Edwards R, Zweckstetter M, Melki R, Stefanis L, Lashuel HA, Sulzer D, Vekrellis K, Halliday GM, Tomlinson JJ, Schlossmacher M, Jensen PH, Schulze-Hentrich J, Riess O, et al. Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. Npj Parkinson's Disease. 7: 65. PMID 34312398 DOI: 10.1038/s41531-021-00203-9  0.326
2021 Sircar E, Rai SR, Wilson MA, Schlossmacher MG, Sengupta R. Neurodegeneration: Impact of S-nitrosylated Parkin, DJ-1 and PINK1 on Parkinson's disease. Archives of Biochemistry and Biophysics. 108869. PMID 33819447 DOI: 10.1016/j.abb.2021.108869  0.358
2021 Tokarew JM, El-Kodsi DN, Lengacher NA, Fehr TK, Nguyen AP, Shutinoski B, O'Nuallain B, Jin M, Khan JM, Ng ACH, Li J, Jiang Q, Zhang M, Wang L, Sengupta R, ... ... Schlossmacher MG, et al. Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites. Acta Neuropathologica. PMID 33694021 DOI: 10.1007/s00401-021-02285-4  0.734
2020 Dwyer Z, Rudyk C, Situt D, Beauchamp S, Abdali J, Dinesh A, Legancher N, Sun H, Schlossmacher M, Hayley S. Microglia depletion prior to lipopolysaccharide and paraquat treatment differentially modulates behavioral and neuronal outcomes in wild type and G2019S LRRK2 knock-in mice. Brain, Behavior, & Immunity - Health. 5: 100079. PMID 34589856 DOI: 10.1016/j.bbih.2020.100079  0.31
2019 Shutinoski B, Hakimi M, Harmsen IE, Lunn M, Rocha J, Lengacher N, Zhou YY, Khan J, Nguyen A, Hake-Volling Q, El-Kodsi D, Li J, Alikashani A, Beauchamp C, Majithia J, ... ... Schlossmacher MG, et al. alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. Science Translational Medicine. 11. PMID 31554740 DOI: 10.1126/Scitranslmed.Aas9292  0.746
2019 Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, Suchowersky O, Rajput A, Lafontaine AL, Mestre T, Appel-Cresswell S, Kalia SK, Schoffer K, Zurowski M, Postuma RB, et al. Canadian guideline for Parkinson disease. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 191: E989-E1004. PMID 31501181 DOI: 10.1503/Cmaj.181504  0.33
2019 Shutinoski B, Patel R, Tomlinson JJ, Schlossmacher MG, Sad S. Ripk3 licenced protection against microbial infection in the absence of Caspase1-11 inflammasome. Microbes and Infection. PMID 31430539 DOI: 10.1016/J.Micinf.2019.08.002  0.723
2018 Kim KS, Marcogliese PC, Yang J, Callaghan SM, Resende V, Abdel-Messih E, Marras C, Visanji NP, Huang J, Schlossmacher MG, Trinkle-Mulcahy L, Slack RS, Lang AE, Park DS. Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 29760073 DOI: 10.1073/Pnas.1718946115  0.397
2017 Eidson LN, Kannarkat GT, Barnum CJ, Chang J, Chung J, Caspell-Garcia C, Taylor P, Mollenhauer B, Schlossmacher MG, Ereshefsky L, Yen M, Kopil C, Frasier M, Marek K, Hertzberg VS, et al. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease. Journal of Neuroinflammation. 14: 164. PMID 28821274 DOI: 10.1186/S12974-017-0935-1  0.434
2017 Tomlinson JJ, Shutinoski B, Dong L, Meng F, Elleithy D, Lengacher NA, Nguyen AP, Cron GO, Jiang Q, Roberson ED, Nussbaum RL, Majbour NK, El-Agnaf OM, Bennett SA, Lagace DC, ... ... Schlossmacher MG, et al. Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 28477284 DOI: 10.1007/S00702-017-1726-7  0.749
2016 Schlossmacher MG, Tomlinson JJ, Santos G, Shutinoski B, Brown EG, Manuel D, Mestre T. Modeling Idiopathic Parkinson Disease as a Complex Illness Can Inform Incidence Risk in Healthy Adults: The PR EDIGT Score. The European Journal of Neuroscience. PMID 27859866 DOI: 10.1111/Ejn.13476  0.749
2016 Shutinoski B, Alturki NA, Rijal D, Bertin J, Gough PJ, Schlossmacher MG, Sad S.. K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo. Cell Death Differ.. 10: 1628-37. PMID 27258786 DOI: 10.1038/Cdd.2016.51  0.724
2016 Kruse N, Schlossmacher MG, Schulz-Schaeffer WJ, Vanmechelen E, Vanderstichele H, El-Agnaf OM, Mollenhauer B. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. Plos One. 11: e0153564. PMID 27116005 DOI: 10.1371/Journal.Pone.0153564  0.383
2015 Mollenhauer B, Parnetti L, Rektorova I, Kramberger MG, Pikkarainen M, Schulz-Schaeffer WJ, Aarsland D, Svenningsson P, Farotti L, Verbeek MM, Schlossmacher MG. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Journal of Neurochemistry. PMID 26452984 DOI: 10.1111/Jnc.13390  0.444
2015 Rocha JD, Schlossmacher MG, Philpott DJ. LRRK2 and Nod2 promote lysozyme sorting in Paneth cells. Nature Immunology. 16: 898-900. PMID 26287588 DOI: 10.1038/Ni.3255  0.341
2015 Gray MT, Munoz DG, Schlossmacher MG, Gray DA, Woulfe JM. Protective effect of vagotomy suggests source organ for Parkinson's disease. Annals of Neurology. PMID 26267415 DOI: 10.1002/Ana.24501  0.349
2015 Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, ... ... Schlossmacher MG, et al. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain : a Journal of Neurology. 138: 2659-71. PMID 26220939 DOI: 10.1093/Brain/Awv202  0.41
2015 Laurens B, Constantinescu R, Freeman R, Gerhard A, Jellinger K, Jeromin A, Krismer F, Mollenhauer B, Schlossmacher MG, Shaw LM, Verbeek MM, Wenning GK, Winge K, Zhang J, Meissner WG. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. Neurobiology of Disease. 80: 29-41. PMID 25982836 DOI: 10.1016/J.Nbd.2015.05.004  0.307
2014 Kuzdas-Wood D, Stefanova N, Jellinger KA, Seppi K, Schlossmacher MG, Poewe W, Wenning GK. Towards translational therapies for multiple system atrophy. Progress in Neurobiology. 118: 19-35. PMID 24598411 DOI: 10.1016/J.Pneurobio.2014.02.007  0.36
2014 Gray MT, Munoz DG, Gray DA, Schlossmacher MG, Woulfe JM. Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 991-8. PMID 24352892 DOI: 10.1002/Mds.25779  0.383
2013 Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, ... ... Schlossmacher MG, et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 81: 1531-7. PMID 24068787 DOI: 10.1212/Wnl.0B013E3182A95818  0.352
2013 Mollenhauer B, Trautmann E, Sixel-Döring F, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Focke NK, Kumar KR, Lohmann K, Klein C, Schlossmacher MG, Kohnen R, Friede T, Trenkwalder C, et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology. 81: 1226-34. PMID 23997153 DOI: 10.1212/Wnl.0B013E3182A6Cbd5  0.364
2013 Ekholm-Reed S, Goldberg MS, Schlossmacher MG, Reed SI. Parkin-dependent degradation of the F-box protein Fbw7β promotes neuronal survival in response to oxidative stress by stabilizing Mcl-1. Molecular and Cellular Biology. 33: 3627-43. PMID 23858059 DOI: 10.1128/Mcb.00535-13  0.4
2013 Gauvin L, Bennett S, Liu H, Hakimi M, Schlossmacher M, Majithia J, Brown EG. Respiratory infection of mice with mammalian reoviruses causes systemic infection with age and strain dependent pneumonia and encephalitis Virology Journal. 10. PMID 23453057 DOI: 10.1186/1743-422X-10-67  0.341
2013 Mollenhauer B, Trautmann E, Taylor P, Manninger P, Sixel-Döring F, Ebentheuer J, Trenkwalder C, Schlossmacher MG. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neuroscience Letters. 532: 44-8. PMID 23149132 DOI: 10.1016/J.Neulet.2012.11.004  0.423
2012 Rousseaux MW, Marcogliese PC, Qu D, Hewitt SJ, Seang S, Kim RH, Slack RS, Schlossmacher MG, Lagace DC, Mak TW, Park DS. Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America. 109: 15918-23. PMID 23019375 DOI: 10.1073/Pnas.1205102109  0.44
2012 Bidinosti M, Shimshek DR, Mollenhauer B, Marcellin D, Schweizer T, Lotz GP, Schlossmacher MG, Weiss A. Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. The Journal of Biological Chemistry. 287: 33691-705. PMID 22843695 DOI: 10.1074/Jbc.M112.379792  0.384
2012 Kitada T, Tomlinson JJ, Ao HS, Grimes DA, Schlossmacher MG. Considerations regarding the etiology and future treatment of autosomal recessive versus idiopathic Parkinson disease. Current Treatment Options in Neurology. 14: 230-40. PMID 22547255 DOI: 10.1007/S11940-012-0175-8  0.43
2012 Kruse N, Schulz-Schaeffer WJ, Schlossmacher MG, Mollenhauer B. Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid. Methods (San Diego, Calif.). 56: 514-8. PMID 22465793 DOI: 10.1016/J.Ymeth.2012.03.016  0.433
2012 Mollenhauer B, Trautmann E, Otte B, Ng J, Spreer A, Lange P, Sixel-Döring F, Hakimi M, VonSattel JP, Nussbaum R, Trenkwalder C, Schlossmacher MG. α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system Journal of Neural Transmission. 119: 739-746. PMID 22426833 DOI: 10.1007/S00702-012-0784-0  0.341
2012 Sardi SP, Singh P, Cheng SH, Shihabuddin LS, Schlossmacher MG. Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models. Neuro-Degenerative Diseases. 10: 195-202. PMID 22327140 DOI: 10.1159/000335038  0.461
2011 Ding H, Sarokhan AK, Roderick SS, Bakshi R, Maher NE, Ashourian P, Kan CG, Chang S, Santarlasci A, Swords KE, Ravina BM, Hayes MT, Sohur US, Wills AM, Flaherty AW, ... ... Schlossmacher MG, et al. Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2283-6. PMID 21953863 DOI: 10.1002/Mds.23934  0.395
2011 Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, Passini MA, Grabowski GA, Schlossmacher MG, Sidman RL, Cheng SH, Shihabuddin LS. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America. 108: 12101-6. PMID 21730160 DOI: 10.1073/Pnas.1108197108  0.427
2011 Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G, Venderova K, Girardin SE, Bulman DE, Scherzer CR, LaVoie MJ, Gris D, Park DS, Angel JB, Shen J, ... ... Schlossmacher MG, et al. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. Journal of Neural Transmission (Vienna, Austria : 1996). 118: 795-808. PMID 21552986 DOI: 10.1007/S00702-011-0653-2  0.422
2011 Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, Kolodziej P, Kahn I, Saftig P, Woulfe J, Rochet JC, Glicksman MA, Cheng SH, Grabowski GA, Shihabuddin LS, ... Schlossmacher MG, et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Annals of Neurology. 69: 940-53. PMID 21472771 DOI: 10.1002/Ana.22400  0.403
2011 Klein C, Krainc D, Schlossmacher MG, Lang AE. Translational research in neurology and neuroscience 2011: movement disorders. Archives of Neurology. 68: 709-16. PMID 21320985 DOI: 10.1001/Archneurol.2011.11  0.317
2011 Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. The Lancet. Neurology. 10: 230-40. PMID 21317042 DOI: 10.1016/S1474-4422(11)70014-X  0.373
2011 Mollenhauer B, Schulz-Schaeffer WJ, Schlossmacher MG. CSF α-synuclein, tau, and amyloid β in Parkinson's disease – Authors' reply Lancet Neurology. 10: 681-683. DOI: 10.1016/S1474-4422(11)70161-2  0.361
2010 Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomarkers in Medicine. 4: 683-99. PMID 20945981 DOI: 10.2217/Bmm.10.90  0.417
2010 Schlossmacher MG, Mollenhauer B. Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials. Biomarkers in Medicine. 4: 647-50. PMID 20945977 DOI: 10.2217/Bmm.10.93  0.427
2009 Cronin KD, Ge D, Manninger P, Linnertz C, Rossoshek A, Orrison BM, Bernard DJ, El-Agnaf OMA, Schlossmacher MG, Nussbaum RL, Chiba-Falek O. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human α-synuclein in transgenic mouse brain Human Molecular Genetics. 18: 3274-3285. PMID 19498036 DOI: 10.1093/Hmg/Ddp265  0.462
2009 Baulac S, Lu H, Strahle J, Yang T, Goldberg MS, Shen J, Schlossmacher MG, Lemere CA, Lu Q, Xia W. Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brains. Molecular Neurodegeneration. 4: 12. PMID 19243613 DOI: 10.1186/1750-1326-4-12  0.374
2009 Cullen V, Lindfors M, Ng J, Paetau A, Swinton E, Kolodziej P, Boston H, Saftig P, Woulfe J, Feany MB, Myllykangas L, Schlossmacher MG, Tyynelä J. Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Molecular Brain. 2: 5. PMID 19203374 DOI: 10.1186/1756-6606-2-5  0.446
2009 Schlossmacher MG. Quantification of total α-synuclein in cerebrospinal fluid by ELISA: Cross-sectional investigation of subjects with dementia and parkinsonism Alzheimers & Dementia. 5. DOI: 10.1016/J.Jalz.2009.05.574  0.31
2008 Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG. Multiple system atrophy: a primary oligodendrogliopathy. Annals of Neurology. 64: 239-46. PMID 18825660 DOI: 10.1002/Ana.21465  0.371
2008 Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, Ney PA, Ng J, McGoldrick M, Mollenhauer B, Bresnick EH, Schlossmacher MG. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proceedings of the National Academy of Sciences of the United States of America. 105: 10907-12. PMID 18669654 DOI: 10.1073/Pnas.0802437105  0.415
2008 Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, ... Schlossmacher MG, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Experimental Neurology. 213: 315-25. PMID 18625222 DOI: 10.1016/J.Expneurol.2008.06.004  0.374
2008 Shimura H, Schlossmacher M, Hattori N, Mizuno Y, Kosik K, Selkoe D. Interaction between parkin and alpha-synuclein Journal of Neurochemistry. 81: 3-3. DOI: 10.1046/J.1471-4159.81.S1.49_4.X  0.468
2007 LaVoie MJ, Cortese GP, Ostaszewski BL, Schlossmacher MG. The effects of oxidative stress on parkin and other E3 ligases. Journal of Neurochemistry. 103: 2354-68. PMID 17883392 DOI: 10.1111/J.1471-4159.2007.04911.X  0.437
2007 Klein C, Schlossmacher MG. Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology. 69: 2093-104. PMID 17761553 DOI: 10.1212/01.Wnl.0000271880.27321.A7  0.443
2007 Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. The Lancet. Neurology. 6: 652-62. PMID 17582365 DOI: 10.1016/S1474-4422(07)70174-6  0.372
2007 Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 3338-46. PMID 17376994 DOI: 10.1523/Jneurosci.0285-07.2007  0.388
2007 Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR. Molecular markers of early Parkinson's disease based on gene expression in blood. Proceedings of the National Academy of Sciences of the United States of America. 104: 955-60. PMID 17215369 DOI: 10.1073/Pnas.0610204104  0.603
2007 Lieberman RL, Wustman BA, Huertas P, Powe AC, Pine CW, Khanna R, Schlossmacher MG, Ringe D, Petsko GA. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nature Chemical Biology. 3: 101-7. PMID 17187079 DOI: 10.1038/Nchembio850  0.32
2006 Klein C, Schlossmacher MG. The genetics of Parkinson disease: Implications for neurological care. Nature Clinical Practice. Neurology. 2: 136-46. PMID 16932540 DOI: 10.1038/Ncpneuro0126  0.428
2006 Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG, El-Agnaf OM. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochemical and Biophysical Research Communications. 349: 162-6. PMID 16930553 DOI: 10.1016/J.Bbrc.2006.08.024  0.391
2006 Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. The Journal of Biological Chemistry. 281: 29739-52. PMID 16847063 DOI: 10.1074/Jbc.M600933200  0.361
2006 Rosen KM, Veereshwarayya V, Moussa CE, Fu Q, Goldberg MS, Schlossmacher MG, Shen J, Querfurth HW. Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. The Journal of Biological Chemistry. 281: 12809-16. PMID 16517603 DOI: 10.1074/Jbc.M512649200  0.314
2006 El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 419-25. PMID 16507759 DOI: 10.1096/Fj.03-1449Com  0.412
2005 LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ. Dopamine covalently modifies and functionally inactivates parkin. Nature Medicine. 11: 1214-21. PMID 16227987 DOI: 10.1038/Nm1314  0.426
2005 Pramstaller PP, Schlossmacher MG, Jacques TS, Scaravilli F, Eskelson C, Pepivani I, Hedrich K, Adel S, Gonzales-McNeal M, Hilker R, Kramer PL, Klein C. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Annals of Neurology. 58: 411-22. PMID 16130111 DOI: 10.1002/Ana.20587  0.411
2005 Schlossmacher MG, Shimura H. Parkinson's disease: assays for the ubiquitin ligase activity of neural Parkin. Methods in Molecular Biology (Clifton, N.J.). 301: 351-69. PMID 15917645 DOI: 10.1385/1-59259-895-1:351  0.459
2005 Bandopadhyay R, Kingsbury AE, Muqit MM, Harvey K, Reid AR, Kilford L, Engelender S, Schlossmacher MG, Wood NW, Latchman DS, Harvey RJ, Lees AJ. Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition Neurobiology of Disease. 20: 401-411. PMID 15894486 DOI: 10.1016/J.Nbd.2005.03.021  0.425
2004 Baulac S, LaVoie MJ, Strahle J, Schlossmacher MG, Xia W. Dimerization of Parkinson's disease-causing DJ-1 and formation of high molecular weight complexes in human brain. Molecular and Cellular Neurosciences. 27: 236-46. PMID 15519239 DOI: 10.1016/J.Mcn.2004.06.014  0.45
2004 Johnson KA, Rentz DM, Moran EK, Becker JA, Schlossmacher MG, Sudarsky LR, Fischman AJ. O4-06-06 Combined dopamine transporter and FDG pet in DLB, AD, and PD Neurobiology of Aging. 25. DOI: 10.1016/S0197-4580(04)80293-8  0.303
2003 Cookson MR, Lockhart PJ, McLendon C, O'Farrell C, Schlossmacher M, Farrer MJ. RING finger 1 mutations in Parkin produce altered localization of the protein. Human Molecular Genetics. 12: 2957-65. PMID 14519684 DOI: 10.1093/Hmg/Ddg328  0.355
2002 Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, Ochiishi T, Shimura H, Sharon R, Hattori N, Langston JW, Mizuno Y, Hyman BT, Selkoe DJ, Kosik KS. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. The American Journal of Pathology. 160: 1655-67. PMID 12000718 DOI: 10.1016/S0002-9440(10)61113-3  0.409
2001 Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science (New York, N.Y.). 293: 263-9. PMID 11431533 DOI: 10.1126/Science.1060627  0.455
1990 Podlisny MB, Mammen AL, Schlossmacher MG, Palmert MR, Younkin SG, Selkoe DJ. Detection of soluble forms of the beta-amyloid precursor protein in human plasma. Biochemical and Biophysical Research Communications. 167: 1094-101. PMID 2138892 DOI: 10.1016/0006-291X(90)90635-Z  0.3
Show low-probability matches.